[管理者用] 最新ニュース(タブ)
サブ-ナビゲーション
information
News
Corporate Guide
Business
Investor Relations
Sustainability
Contact Us
[管理者用] 最新ニュース(タブ)
What’s new
Press Release
Investor Relations
Information
2026/06/23
Update on Discussions on the Succession of the GMP-Compliant Cell Processing CDMO Business
2026/06/23
Execution of a Patent License Agreement with 10x Genomics, Inc. for Spatial Products “Seeker™” and “Trekker™”
2026/06/11
Notice of Delisting of Company Shares
（104KB）
2026/05/20
Notice regarding Resolutions to Approve Share Consolidation, Abolition of Provision on Share Units, and Partial Amendment of AOI
（214KB）
2026/05/13
Implementation of Structural Reforms for Profit Improvement
（183KB）
Read More
2026/06/23
Update on Discussions on the Succession of the GMP-Compliant Cell Processing CDMO Business
2026/06/23
Execution of a Patent License Agreement with 10x Genomics, Inc. for Spatial Products “Seeker™” and “Trekker™”
2026/02/06
Waskyra™, a Gene Therapy Manufactured Using RetroNectin®, Receives U.S. and EU Marketing Authorization Approvals
2025/09/16
Completion of Clinical Trial Notification Process in Japan for Confirmatory Study of NY-ESO-1・siTCR™ Gene Therapy
2025/09/12
Announcement of “Takara Bio Group Long-Term Vision 2050”
Read More
2026/06/11
Notice of Delisting of Company Shares
（104KB）
2026/05/20
Notice regarding Resolutions to Approve Share Consolidation, Abolition of Provision on Share Units, and Partial Amendment of AOI
（214KB）
2026/05/13
Implementation of Structural Reforms for Profit Improvement
（183KB）
2026/05/13
Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP)
（560KB）
2026/05/08
[Correction] Notice of the Convening of an Extraordinary General Meeting of Shareholders.
（175KB）
Read More
2026/05/07
Takara Bio to Present Latest Advances in Gene and Cell Therapy at ASGCT 2026
2024/05/02
Takara Bio to Present Advances in Gene and Cell Research at ASGCT 2024
Read More
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
menu
JA
EN
contact
gnavi-box
